SEHK:1952Biotechs
Everest Medicines (SEHK:1952): Revisiting Valuation After Recent Share Price Weakness
Everest Medicines (SEHK:1952) inched up about 2% in the latest session, a small move that still draws attention given the stock’s weaker performance over the past 3 months and year.
See our latest analysis for Everest Medicines.
At HK$44.84, the latest move comes against a weak backdrop, with the 30 day share price return of negative 5.9% and a much steeper 90 day share price return of negative 23%. This suggests recent momentum is fading despite a robust three year total shareholder return...